First AD

Second AD

Floortje J Backes, MD, is a gynecologic oncologist and a professor in the College of Medicine at The Ohio State University Wexner Medical Center and the OSUCCC – James.

Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

Additional Potential Roles for Mirvatuximab Soravtansine and Other ADCs in Ovarian Cancer

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Ovarian Cancer

GSK-22-OSD1278 - /clinical/ovarian-cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.